Please login to the form below

Not currently logged in
Email:
Password:

Mark Booth joins Probiodrug

He becomes chief business officer

Probiodrug Mark BoothHalle, Germany-based Probiodrug has appointed Mark Booth as its chief business officer and member of its management board.

Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

He brings over 30 years of biopharmaceutical experience to Probiodrug and has held key positions at Abbott Laboratories, Immunex Corporation and Takeda Pharmaceuticals, where he served as president of its North America operations.

Dr Erich Platzer, chairman of Probiodrug's supervisory board, said: “Mark's broad business background and proven track record make him a valuable addition to our management board.

“His extensive experience in business development and investor relations will be instrumental to propel Probiodrug's strategy internationally and in particular [in] the United States.”

Booth said: “This is truly a unique opportunity and I look forward to working with the team as we advance new and novel therapeutic treatments for Alzheimer's patients.”

31st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics